
Opinion|Videos|January 22, 2024
The Impact of Biomarkers in Clinical Decision-Making and Emergent Agents in HR+/HER2- Metastatic Breast Cancer
Author(s)Virginia G. Kaklamani, MD
Virginia Kaklamani, MD, DSc, explains that in second-line treatment of metastatic HR+/HER2- breast cancer after CDK4/6 inhibitors, biomarker testing guides the choice between therapies based on the safety and resistance mutation profiles.
Episodes in this series






































